Montiva
Generic Name
Montelukast
Manufacturer
General Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| montiva 4 mg flash tablet | ৳ 7.00 | ৳ 70.00 |
Description
Overview of the medicine
Montiva 4 mg Flash Tablet contains Montelukast, a leukotriene receptor antagonist, used for the prophylaxis and chronic treatment of asthma, including prevention of exercise-induced bronchoconstriction, and for the relief of symptoms of seasonal and perennial allergic rhinitis.
Uses & Indications
Dosage
Adults
Not typically for adults (4 mg flash tablet is primarily pediatric). Adult dosage for Montelukast is usually 10 mg tablet daily.
Elderly
No dosage adjustment is generally required for elderly patients.
Renal_impairment
No dosage adjustment is required for patients with renal impairment.
Pediatric_2_to_5_years
One 4 mg flash tablet daily, taken in the evening. For chronic asthma and seasonal allergic rhinitis.
Pediatric_6_to_14_years
Not for 4 mg flash tablet; typically 5 mg chewable tablet daily.
How to Take
Take Montiva 4 mg Flash Tablet once daily in the evening. For flash tablets, place on the tongue, allow it to rapidly disintegrate, then swallow with or without water. Do not chew the tablet.
Mechanism of Action
Montelukast is a potent, orally active, and selective leukotriene receptor antagonist that specifically inhibits the cysteinyl leukotriene CysLT1 receptor. Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are eicosanoids released from various cells (e.g., mast cells, eosinophils) and are associated with the pathogenesis of asthma and allergic rhinitis. By blocking the CysLT1 receptor, Montelukast inhibits the bronchoconstriction, mucus secretion, vascular permeability, and eosinophil recruitment induced by these leukotrienes, thereby improving asthma and allergic rhinitis symptoms.
Pharmacokinetics
Onset
Within 1 day for improvement in asthma control.
Excretion
Primarily excreted in feces (approximately 86%) via bile; renal excretion is minimal (less than 0.2%).
Half life
Plasma half-life ranges from 2.7 to 5.5 hours.
Absorption
Rapidly absorbed after oral administration. Mean oral bioavailability is 64%. Peak plasma concentrations (Tmax) are reached approximately 2-4 hours after administration.
Metabolism
Extensively metabolized in the liver, primarily by CYP3A4, CYP2C9, and CYP2A6. Metabolites are pharmacologically inactive.
Side Effects
Contraindications
- Hypersensitivity to Montelukast or any of its excipients.
Drug Interactions
Rifampin
May decrease the plasma concentration of Montelukast, requiring careful monitoring.
Phenobarbital
May decrease the area under the plasma concentration-time curve (AUC) of Montelukast by approximately 40%.
Other CYP inducers/inhibitors
Montelukast is a substrate of CYP3A4, 2C9, and 2A6. Co-administration with potent inducers or inhibitors of these enzymes may alter Montelukast plasma levels.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of the reach and sight of children.
Overdose
In post-marketing experience and clinical trials, there have been reports of acute overdose with Montelukast. The most frequently reported adverse events were abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity. There is no specific antidote; symptomatic and supportive measures are advised.
Pregnancy & Lactation
Use during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus. Montelukast is excreted in human breast milk; caution should be exercised when administered to a nursing mother.
Side Effects
Contraindications
- Hypersensitivity to Montelukast or any of its excipients.
Drug Interactions
Rifampin
May decrease the plasma concentration of Montelukast, requiring careful monitoring.
Phenobarbital
May decrease the area under the plasma concentration-time curve (AUC) of Montelukast by approximately 40%.
Other CYP inducers/inhibitors
Montelukast is a substrate of CYP3A4, 2C9, and 2A6. Co-administration with potent inducers or inhibitors of these enzymes may alter Montelukast plasma levels.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of the reach and sight of children.
Overdose
In post-marketing experience and clinical trials, there have been reports of acute overdose with Montelukast. The most frequently reported adverse events were abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity. There is no specific antidote; symptomatic and supportive measures are advised.
Pregnancy & Lactation
Use during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus. Montelukast is excreted in human breast milk; caution should be exercised when administered to a nursing mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2 to 3 years from the date of manufacture.
Availability
Pharmacies, Hospitals
Approval Status
Approved by DGDA/FDA
Patent Status
Generic available
Clinical Trials
Extensive clinical trials have demonstrated the efficacy and safety of Montelukast in the prophylaxis and chronic treatment of asthma and allergic rhinitis across various age groups. Studies confirm its role as a well-tolerated leukotriene receptor antagonist.
Lab Monitoring
- Routine laboratory monitoring is not typically required. Liver function tests may be considered if there are signs or symptoms of hepatic impairment.
Doctor Notes
- Emphasize the importance of daily, evening administration for optimal therapeutic effect, not for PRN use.
- Educate patients and caregivers about potential neuropsychiatric symptoms and the need for prompt reporting.
- Reiterate that Montelukast is not a bronchodilator for acute asthma exacerbations and rescue medication should always be available.
Patient Guidelines
- Take Montiva daily in the evening, as prescribed, even if you have no symptoms or your asthma is well-controlled.
- Montiva is not for treating acute asthma attacks. Always carry your rescue inhaler for sudden asthma symptoms.
- Inform your doctor immediately if you experience any behavioral changes, mood changes, or thoughts of self-harm.
- Do not stop taking other asthma medications unless advised by your doctor.
Missed Dose Advice
If a dose is missed, take the next dose at the regular scheduled time. Do not take a double dose to compensate for the missed one.
Driving Precautions
Some patients may experience dizziness or drowsiness while taking Montelukast. Caution is advised when driving or operating machinery until you know how the medicine affects you.
Lifestyle Advice
- Identify and avoid triggers that worsen your asthma or allergic rhinitis.
- Maintain a healthy lifestyle with regular exercise and a balanced diet.
- Avoid smoking or exposure to secondhand smoke.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Montiva Brand
Other medicines available under the same brand name
